-
1
-
-
25644453616
-
Glycemic characteristics in continuously monitored patients with type 1 and type 2 diabetes: Normative values
-
Bode BW, Schwartz S, Stubbs HA, et al. Glycemic characteristics in continuously monitored patients with type 1 and type 2 diabetes: normative values. Diabetes Care. 2005;28:2361-2366.
-
(2005)
Diabetes Care.
, vol.28
, pp. 2361-2366
-
-
Bode, B.W.1
Schwartz, S.2
Stubbs, H.A.3
-
2
-
-
65549113825
-
Acute hyperinsulinemia raises plasma interleukin-6 in both nondiabetic and type 2 diabetes mellitus subjects, and this effect is inversely associated with body mass index
-
Ruge T, Lockton JA, Renstrom F, et al. Acute hyperinsulinemia raises plasma interleukin-6 in both nondiabetic and type 2 diabetes mellitus subjects, and this effect is inversely associated with body mass index. Metabolism. 2009;58:860-866.
-
(2009)
Metabolism.
, vol.58
, pp. 860-866
-
-
Ruge, T.1
Lockton, J.A.2
Renstrom, F.3
-
3
-
-
33746110778
-
Hyperandrogenism, insulin resistance and hyperinsulinemia as cardiovascular risk factors in diabetes mellitus
-
Garcia-Romero G, Escobar-Morreale HF. Hyperandrogenism, insulin resistance and hyperinsulinemia as cardiovascular risk factors in diabetes mellitus. Curr Diabetes Rev. 2006;2:39-49.
-
(2006)
Curr Diabetes Rev.
, vol.2
, pp. 39-49
-
-
Garcia-Romero, G.1
Escobar-Morreale, H.F.2
-
4
-
-
84873683616
-
Insulin resistance/hyperinsulinemia and cancer mortality: The Cremona study at the 15th year of follow-up
-
Perseghin G, Calori G, Lattuada G, et al. Insulin resistance/ hyperinsulinemia and cancer mortality: the Cremona study at the 15th year of follow-up. Acta Diabetol. 2012;49:421-428.
-
(2012)
Acta Diabetol.
, vol.49
, pp. 421-428
-
-
Perseghin, G.1
Calori, G.2
Lattuada, G.3
-
5
-
-
77950656511
-
Temporal patterns in overweight and obesity in type 1 diabetes
-
Conway B, Miller RG, Costacou T, et al. Temporal patterns in overweight and obesity in type 1 diabetes. Diabet Med. 2010;27: 398-404.
-
(2010)
Diabet Med.
, vol.27
, pp. 398-404
-
-
Conway, B.1
Miller, R.G.2
Costacou, T.3
-
6
-
-
0037711693
-
Coexistence of type 1 and type 2 diabetes mellitus: Double diabetes?
-
Libman IM, Becker DJ. Coexistence of type 1 and type 2 diabetes mellitus: "double" diabetes? Pediatr Diabetes. 2003;4:110-113.
-
(2003)
Pediatr Diabetes.
, vol.4
, pp. 110-113
-
-
Libman, I.M.1
Becker, D.J.2
-
7
-
-
34347332293
-
Pramlintide acetate injection for the treatment of type 1 and type 2 diabetes mellitus
-
Singh-Franco D, Robles G, Gazze D. Pramlintide acetate injection for the treatment of type 1 and type 2 diabetes mellitus. Clin Ther. 2007;29:535-562.
-
(2007)
Clin Ther.
, vol.29
, pp. 535-562
-
-
Singh-Franco, D.1
Robles, G.2
Gazze, D.3
-
8
-
-
8144228619
-
Amylin replacement with pramlintide as an adjunct to insulin therapy improves long-term glycaemic and weight control in type 1 diabetes mellitus: A 1-year, randomized controlled trial
-
Ratner RE, Dickey R, Fineman M, et al. Amylin replacement with pramlintide as an adjunct to insulin therapy improves long-term glycaemic and weight control in type 1 diabetes mellitus: a 1-year, randomized controlled trial. Diabet Med. 2004;21:1204-1212.
-
(2004)
Diabet Med.
, vol.21
, pp. 1204-1212
-
-
Ratner, R.E.1
Dickey, R.2
Fineman, M.3
-
9
-
-
53849095733
-
Glucagon-like peptide receptor agonists and dipeptidyl peptidase-4 inhibitors in the treatment of diabetes: A review of clinical trials
-
Madsbad S, Krarup T, Deacon CF, et al. Glucagon-like peptide receptor agonists and dipeptidyl peptidase-4 inhibitors in the treatment of diabetes: a review of clinical trials. Curr Opin Clin Nutr Metab Care. 2008;11:491-499.
-
(2008)
Curr Opin Clin Nutr Metab Care.
, vol.11
, pp. 491-499
-
-
Madsbad, S.1
Krarup, T.2
Deacon, C.F.3
-
10
-
-
67651173077
-
Incretin-based therapies for type 2 diabetes mellitus
-
Lovshin JA, Drucker DJ. Incretin-based therapies for type 2 diabetes mellitus. Nat Rev Endocrinol. 2009;5:262-269.
-
(2009)
Nat Rev Endocrinol.
, vol.5
, pp. 262-269
-
-
Lovshin, J.A.1
Drucker, D.J.2
-
11
-
-
80054690193
-
Four weeks of treatment with liraglutide reduces insulin dose without loss of glycemic control in type 1 diabetic patients with and without residual {beta}-cell function
-
Kielgast U, Krarup T, Holst JJ, et al. Four weeks of treatment with liraglutide reduces insulin dose without loss of glycemic control in type 1 diabetic patients with and without residual {beta}-cell function. Diabetes Care. 2011;34:1463-1468.
-
(2011)
Diabetes Care.
, vol.34
, pp. 1463-1468
-
-
Kielgast, U.1
Krarup, T.2
Holst, J.J.3
-
12
-
-
72249103423
-
Effects of exenatide alone and in combination with daclizumab on beta-cell function in long-standing type 1 diabetes
-
Rother KI, Spain LM, Wesley RA, et al. Effects of exenatide alone and in combination with daclizumab on beta-cell function in long-standing type 1 diabetes. Diabetes Care. 2009;32:2251-2257.
-
(2009)
Diabetes Care.
, vol.32
, pp. 2251-2257
-
-
Rother, K.I.1
Spain, L.M.2
Wesley, R.A.3
-
13
-
-
79959392262
-
Liraglutide as additional treatment for type 1 diabetes
-
Varanasi A, Bellini N, Rawal D, et al. Liraglutide as additional treatment for type 1 diabetes. Eur J Endocrinol. 2011;165:77-84.
-
(2011)
Eur J Endocrinol.
, vol.165
, pp. 77-84
-
-
Varanasi, A.1
Bellini, N.2
Rawal, D.3
-
14
-
-
64749099781
-
Glycemia and cardiovascular disease in type 1 diabetes mellitus
-
Wajchenberg BL, Feitosa AC, Rassi N, et al. Glycemia and cardiovascular disease in type 1 diabetes mellitus. Endocr Pract. 2008;14:912-923.
-
(2008)
Endocr Pract.
, vol.14
, pp. 912-923
-
-
Wajchenberg, B.L.1
Feitosa, A.C.2
Rassi, N.3
-
15
-
-
65949122087
-
One-year treatment with exenatide improves beta-cell function, compared with insulin glargine, in metformin-treated type 2 diabetic patients: A randomized, controlled trial
-
Bunck MC, Diamant M, Corner A, et al. One-year treatment with exenatide improves beta-cell function, compared with insulin glargine, in metformin-treated type 2 diabetic patients: a randomized, controlled trial. Diabetes Care. 2009;32:762-768.
-
(2009)
Diabetes Care.
, vol.32
, pp. 762-768
-
-
Bunck, M.C.1
Diamant, M.2
Corner, A.3
-
16
-
-
0036828227
-
Glucagon-like peptide-1 promotes islet cell growth and inhibits apoptosis in Zucker diabetic rats
-
Farilla L, Hui H, Bertolotto C, et al. Glucagon-like peptide-1 promotes islet cell growth and inhibits apoptosis in Zucker diabetic rats. Endocrinology. 2002;143:4397-4408.
-
(2002)
Endocrinology.
, vol.143
, pp. 4397-4408
-
-
Farilla, L.1
Hui, H.2
Bertolotto, C.3
-
17
-
-
77952758235
-
Effect of glucagon-like peptide-1 on alpha- and beta-cell function in C-peptide-negative type 1 diabetic patients
-
Kielgast U, Asmar M, Madsbad S, et al. Effect of glucagon-like peptide-1 on alpha- and beta-cell function in C-peptide-negative type 1 diabetic patients. J Clin Endocrinol Metab. 2010;95:2492-2496.
-
(2010)
J Clin Endocrinol Metab.
, vol.95
, pp. 2492-2496
-
-
Kielgast, U.1
Asmar, M.2
Madsbad, S.3
-
18
-
-
53749089728
-
Combination therapy with glucagon-like peptide-1 and gastrin induces beta-cell neogenesis from pancreatic duct cells in human islets transplanted in immunodeficient diabetic mice
-
Suarez-Pinzon WL, Lakey JR, Rabinovitch A. Combination therapy with glucagon-like peptide-1 and gastrin induces beta-cell neogenesis from pancreatic duct cells in human islets transplanted in immunodeficient diabetic mice. Cell Transplant. 2008;17:631-640.
-
(2008)
Cell Transplant.
, vol.17
, pp. 631-640
-
-
Suarez-Pinzon, W.L.1
Lakey, J.R.2
Rabinovitch, A.3
-
19
-
-
34547672616
-
Continuous stimulation of human glucagon-like peptide-1 (7-36) amide in a mouse model (NOD) delays onset of autoimmune type 1 diabetes
-
Zhang J, Tokui Y, Yamagata K, et al. Continuous stimulation of human glucagon-like peptide-1 (7-36) amide in a mouse model (NOD) delays onset of autoimmune type 1 diabetes. Diabetologia. 2007;50:1900-1909.
-
(2007)
Diabetologia.
, vol.50
, pp. 1900-1909
-
-
Zhang, J.1
Tokui, Y.2
Yamagata, K.3
|